I am patenting mutations of my own genome to see whether the 2013 Supreme Court case Association for Molecular Pathology v. Myriad Genetics, Inc. actually ended the 25-year practice of gene patenting—that is, for-profit labs identifying and claiming human genes as intellectual property in order to profit from any medicines or treatment derived from studying those genes. While the ACLU lauded the case as a “win” that ended the monopolistic practice, I believe alarmingly vague language was used in the ruling outcome and have identified a loophole in which human genes can still be patented as intellectual property.

Through this process, I am seeking to find out if I have any more control over my own genome (and its coding functions) than massive corporations do. Following lab protocols including molecular cloning and using plasmid vectors while collaborating with patent attorneys, this project is a conceptual exploration of the American patent system, as I navigate legal systems and distribute NDAs. I am patenting my genes to inform the public on bioprospecting, and to prove that if I am able to get away with it, corporations undoubtedly still can.